Shares of Mangalam Drugs and Organics surged 5 percent on Tuesday, hitting the upper circuit and extending gains for a second straight session, after disclosures showed that an office-linked entity of noted investor Vijay Kedia acquired a stake in the company through a bulk deal.

Mangalam Drugs and Organics has been among the worst-performing micro-cap pharmaceutical stocks in 2025, suffering a prolonged and steep decline. After touching a 52-week high of ₹124.89 on January 1 this year, the stock has collapsed by more than 80 percent, reflecting sustained selling pressure, weak investor confidence, and broader risk aversion toward smaller pharma names.

The company, which manufactures active pharmaceutical ingredients (APIs) and intermediates, currently commands a market capitalisation of about ₹42 crore, placing it firmly in the micro-cap category. Stocks in this segment are particularly sensitive to liquidity shifts and investor perception, making any high-profile entry closely watched.

According to data available on the NSE, Kedia Securities Private Limited an entity associated with ace investor Vijay Kedia purchased around 1.38 lakh shares of Mangalam Drugs and Organics on December 29 through a bulk deal. The shares were acquired at an average price of ₹24.15 per share, translating into a total transaction value of approximately ₹33.28 lakh.

The acquisition price represented a discount of nearly 3 percent to the stock’s previous closing price of ₹24.96. Following the disclosure, the stock was locked in the upper circuit at ₹26.20, reflecting immediate buying interest from the market.

This buying interest comes despite the stock remaining deeply underwater on a medium-term basis. While Mangalam Drugs shares have gained nearly 10 percent over the past five trading sessions, they are still down around 68 percent over the last six months and more than 78 percent so far in 2025.

In absolute terms, the investment size is modest. However, the importance of the transaction lies in the signal rather than the capital deployed. Vijay Kedia is widely tracked by retail and small-cap investors for his contrarian bets and long-term investing philosophy. Even a relatively small entry by an entity linked to him tends to attract disproportionate attention in the micro-cap space.

For a stock that has been under heavy selling pressure and recently hit a fresh 52-week low of ₹22.80, the bulk deal serves as a psychological trigger. It suggests that at least one seasoned market participant sees value or optionality at current depressed levels, even if that conviction is being expressed cautiously.

That said, the transaction does not, by itself, alter the company’s fundamentals or financial trajectory. There has been no accompanying disclosure of operational improvement, earnings recovery, or balance sheet restructuring.